Improvement of motor function in early Parkinson disease by safinamide

F. Stocchi, G. Arnold, M. Onofrj, H. Kwiecinski, A. Szczudlik, A. Thomas, U. Bonuccelli, A. Van Dijk, C. Cattaneo, P. Sala, R. G. Fariello

Research output: Contribution to journalArticlepeer-review


A median safinamide (SAF) dose of 70 mg/day (range 40 to 90 mg/day) increased the percentage of parkinsonian patients improving their motor scores by ≥30% from baseline (responders) after 3 months from 21.4% (placebo) to 37.5% (p <0.05, calculated by logistic regression analysis). In a subgroup of 101 patients under stable treatment with a single dopamine agonist, addition of SAF magnified the response (47.1% responders, mean 4.7-point motor score decrease; p ≥ 0.05). These results suggest that doses of SAF exerting ion channel block and glutamate release inhibition add to its symptomatic effect and warrant exploration of higher doses.

Original languageEnglish
Pages (from-to)746-748
Number of pages3
Issue number4
Publication statusPublished - Aug 24 2004

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Improvement of motor function in early Parkinson disease by safinamide'. Together they form a unique fingerprint.

Cite this